(210) | Number of the EPO application | 18728541 |
(220) | Filing date of the EPO application | 2018.05.18 |
(80) | EPO patent specification publication (B) | EPB nr. 34/2022, 2022.08.24 |
(110) | EPO patent number | 3630723 |
(21) | Number of the application | e 2020 0317 |
(71) | Name(s) of applicant(s), code of the country | Janssen Pharmaceuticals, Inc., US; Katholieke Universiteit Leuven, BE; |
(72) | Name(s) of inventor(s), code of the country | BONFANTI Jean-François, FR; KESTELEYN Bart Rudolf Romanie, BE; BARDIOT Dorothée Alice Marie-Eve, BE; MARCHAND Arnaud Didier M, BE; COESEMANS Erwin, BE; FORTIN Jérôme Michel Claude, FR; MERCEY Guillaume Jean Maurice, FR; RABOISSON Pierre Jean-Marie Bernard, BE; |
(73) | Name(s) of owner(s), code of the country | JANSSEN Pharmaceuticals Inc., US; Katholieke Universiteit Leuven, BE; |
(54) | Title of the invention | SUBSTITUTED INDOLINE DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS |
(13) | Kind-of-document code | A1 |
(51) | International Patent Classification | C07D 209/08 (2006.01.01); A61K 31/403 (2006.01.01); A61P 31/12 (2006.01.01) |
(19) | Country | US |
(41) | Date of publication of the application | 2020.05.31 |
(30) | Priority | 17172237, 2017.05.22, EP |
(86) | International application | PCT/EP2018/063028, 2018.05.18 |
(87) | International publication | WO 2018/215315, 2018.11.29 |